{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461099753
| IUPAC_name = (''RS'')-6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
| image = Fenoldopam.svg
| width = 200px
| image2 = Fenoldopam 3d balls.png
| chirality = [[Racemic mixture]]
<!--Clinical data-->
| tradename = Corlopam
| Drugs.com = {{drugs.com|monograph|fenoldopam}}
| pregnancy_US = B
| legal_US = Rx-only
| routes_of_administration = [[intravenous|IV]]
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = [[Liver|Hepatic]] ([[Cytochrome P450 oxidase|CYP]] not involved)
| elimination_half-life = 5 minutes
| excretion = [[Kidney|Renal]] (90%) and fecal (10%)
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 67227-56-9
| ATC_prefix = C01
| ATC_suffix = CA19
| PubChem = 3341
| IUPHAR_ligand = 939
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00800
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3224
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = INU8H2KAWG 
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D07946
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5002
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 588
<!--Chemical data-->
| C=16 | H=16 | Cl=1 | N=1 | O=3
| molecular_weight = 305.76 g/mol
| smiles = Clc1c3c(cc(O)c1O)C(c2ccc(O)cc2)CNCC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = TVURRHSHRRELCG-UHFFFAOYSA-N
}}

'''Fenoldopam mesylate''' ('''Corlopam''') is a [[drug]] and [[Synthetic chemical|synthetic]] [[benzazepine]] [[chemical derivative|derivative]] which acts as a [[binding selectivity|selective]] [[D1 receptor|D<sub>1</sub> receptor]] [[partial agonist]].<ref>{{cite journal |vauthors=Grenader A, Healy DP |title=Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells |journal=J. Pharmacol. Exp. Ther. |volume=258 |issue=1 |pages=193–8 |date=July 1991 |pmid=1677038 |doi= |url=}}</ref> Fenoldopam is used as an [[antihypertensive]] agent.<ref name="pmid17000789">{{cite journal |vauthors=Oliver WC, Nuttall GA, Cherry KJ, Decker PA, Bower T, Ereth MH |title=A comparison of fenoldopam with dopamine and sodium nitroprusside in patients undergoing cross-clamping of the abdominal aorta |journal=Anesth. Analg. |volume=103 |issue=4 |pages=833–40 |date=October 2006 |pmid=17000789 |doi=10.1213/01.ane.0000237273.79553.9e |url=http://www.anesthesia-analgesia.org/cgi/pmidlookup?view=long&pmid=17000789}}</ref> It was approved by the [[Food and Drug Administration]] (FDA) in September 1997.<ref>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory  accessed November 14, 2011</ref>

== Indications ==

Fenoldopam is used as an antihypertensive agent postoperatively, and also [[intravenous therapy|intravenously (IV)]] to treat a [[hypertensive crisis]].<ref name=pharmnemonics>{{Cite book | author=Shen, Howard | title=Illustrated Pharmacology Memory Cards: PharMnemonics | year=2008 | publisher=Minireview | isbn=1-59541-101-1 | page=9}}</ref>
Since fenoldopam is the only intravenous agent that improves renal perfusion, in theory it could be beneficial in hypertensive patients with concomitant renal insufficiency.<ref>USMLE WORLD 2009 Step1 QBanks, Pharmacology, Pharma50q, Q NO 18</ref>

== Pharmacology ==

Fenoldopam causes arterial/arteriolar [[vasodilation]] leading to a decrease in [[blood pressure]] by activating peripheral D<sub>1</sub> receptors.<ref name = Nichols>{{cite journal |vauthors=Nichols AJ, Ruffolo RR, Brooks DP |title=The pharmacology of fenoldopam |journal=Am. J. Hypertens. |volume=3 |issue=6 Pt 2 |pages=116S–119S |date=June 1990 |pmid=1974439 |doi= |url=}}</ref> It decreases [[afterload]] and also promotes [[sodium]] excretion via specific dopamine receptors along the [[nephron]]. The renal effect of fenoldopam and dopamine may involve physiological antagonism of the renin-angiotensin system in the kidney.<ref>{{cite journal |author=Gildea JJ |title=Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance |journal=Curr. Opin. Nephrol. Hypertens. |volume=18 |issue=1 |pages=28–32 |date=January 2009 |pmid=19077686 |pmc=2847451 |doi=10.1097/MNH.0b013e32831a9e0b |url=}}</ref>
In contrast to dopamine, fenoldopam is a selective D<sub>1</sub> receptor agonist with no effect on beta adrenoceptors, although there is evidence that it may have some alpha-1 <ref>{{cite journal |vauthors=Martin SW, Broadley KJ |title=Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade |journal=Br. J. Pharmacol. |volume=115 |issue=2 |pages=349–55 |date=May 1995 |pmid=7670737 |pmc=1908310 |doi= 10.1111/j.1476-5381.1995.tb15884.x|url=}}</ref> and alpha-2 adrenoceptor antagonist activity.<ref name = Nichols/>  D<sub>1</sub> receptor stimulation activates adenylyl cyclase and raises intracellular cyclic AMP, resulting in vasodilation of most arterial beds, including renal, mesenteric, and coronary arteries.<ref>{{cite journal |vauthors=Hughes AD, Sever PS |title=Action of fenoldopam, a selective dopamine (DA1) receptor agonist, on isolated human arteries |journal=Blood Vessels |volume=26 |issue=2 |pages=119–27 |year=1989 |pmid=2474340 |doi= |url=}}</ref> to cause a reduction in systemic vascular resistance. 
Fenoldopam has a rapid onset of action (4 minutes) and short duration of action (< 10 minutes) and a linear dose response relationship at usual clinical doses.<ref>Epstein, Murray MD, "Diagnosis and Management of Hypertensive Emergencies,"  clinical Cornerstone. Hypertension Vol2. No 1.</ref>

== Side effects ==

Adverse effects include [[headache]], [[Flushing (physiology)|flushing]], [[nausea]], [[hypotension]], [[reflex tachycardia]], and increased [[intraocular pressure]].<ref name="pharmnemonics"/><ref name = NDA/>

== Contraindications, warnings and precautions ==

Fenoldopam mesylate contains sodium metabisulfite, a sulfite that may rarely cause allergic-type reactions including anaphylactic symptoms and asthma in susceptible people. Fenoldopam mesylate administration should be undertaken with caution to patients with [[glaucoma]] or raised [[intraocular pressure]] as fenoldopam raises intraocular pressure.<ref name = NDA>[http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19922se5-005_colopam_lbl.pdf NDA 19-922/S-005]: Corlopam RA06497-R1-9/03 brand of Fenoldopam Mesylate Injection, USP</ref> Concomitant use of fenoldopam with a [[beta-blocker]] should be avoided if possible, as unexpected hypotension can result from beta-blocker inhibition of sympathetic-mediated reflex tachycardia in response to fenoldopam.<ref name = NDA/>

== References ==
{{Reflist|2}}

{{Sympatholytic antihypertensives}}
{{Dopaminergics}}

[[Category:Benzazepines]]
[[Category:D1-receptor agonists]]
[[Category:Phenols]]
[[Category:Chloroarenes]]
[[Category:Peripherally selective drugs]]